The DOI matches its Crossref record.
Clinical Features and Treatment Outcomes of Necrotizing Autoimmune Myopathy
Abstract
IMPORTANCE: Necrotizing autoimmune myopathy (NAM) is characterized pathologically by necrotic muscle fibers with absent or minimal inflammation. It is often accompanied by statin therapy, connective tissue diseases, cancer, and autoantibodies specific for signal recognition particle (SRP) or 3-hydroxy-3-methylglutaryl-coenzyme A reductase (HMGCR). Data are limited concerning differences among etiologic subgroups and treatment outcomes in NAM. OBJECTIVES: To describe the clinical, serologic, and electrophysiologic characteristics of NAM, compare patient subgroups, and determine clinical outcome predictors. DESIGN, SETTING, AND PARTICIPANTS: We conducted a retrospective review of medical records for 63 adult Mayo Clinic patients assigned the clinical and histopathologic diagnosis of NAM from January 1, 2004, through December 31, 2013. Patients were stratified by presumed cause and autoantibody status. MAIN OUTCOMES AND MEASURES: Clinical, electrophysiologic, and pathologic characteristics were collected and compared among patient subgroups. Predictors of response to treatment were identified by univariate logistic regression. RESULTS: Lower extremity weakness predominated (46 [73%]). Distal weakness (26 [41%]), dysphagia (22 [35%]), and dyspnea (23 [37%]) were common. Twenty-two patients (35%) were receiving a statin medication at onset, 6 had cancer, and 3 had a connective tissue disease. The median creatine kinase level was 5326 U/L. In 13 patients (24%), SRP-IgG was detected, and in 17 patients (34%), HMGCR-IgG was detected (one-third of whom had not received statin medication). One patient was dual seropositive. Facial weakness was more common in SRP-IgG-positive patients. Myotonic discharges were more common in statin-associated NAM. Prednisone monotherapy was insufficient to control disease in most patients; 30 (90%) of 32 patients required 2 or more immunotherapeutic agents. Relapse occurred in 16 (55%) of 29 patients during immunosuppressant taper or discontinuation. Predictors of favorable outcome were male sex and use of 2 or more immunotherapeutic agents within 3 months of onset. CONCLUSIONS AND RELEVANCE: Necrotizing autoimmune myopathy was idiopathic in half of this cohort with clinical and histopathologically defined disease. In the remainder, NAM was associated with statin medication, cancer, or connective tissue disease. One in 4 patients was SRP-IgG positive, and 1 in 3 was HMGCR-IgG positive. The disease was usually not controlled by corticosteroid monotherapy. Presentation, course, and outcomes did not differ significantly in seropositive, seronegative, and statin-associated cases. Early aggressive immunosuppressant therapy improved outcomes, and risk of relapse was high during medication dose reduction or withdrawal.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
224th ENMC International Workshop:
Allenbach, Y., Mammen, A. L., Benveniste, O., Stenzel, W., Allenbach, Y., Amato, A., Aussey, A., Benveniste, O., De Bleecker, J., de Groot, I., et al. (2018) · Neuromuscular Disorders · doi:10.1016/j.nmd.2017.09.016 · Cited by 582
Statin-Associated Autoimmune Myopathy
Mammen, A. L. (2016) · New England Journal of Medicine · doi:10.1056/nejmra1515161 · Cited by 366
Immune-mediated necrotizing myopathy: clinical features and pathogenesis
Allenbach, Y., Benveniste, O., Stenzel, W., & Boyer, O. (2020) · Nature Reviews Rheumatology · doi:10.1038/s41584-020-00515-9 · Cited by 335
Clinical features and prognosis in anti-SRP and anti-HMGCR necrotising myopathy
Watanabe, Y., Uruha, A., Suzuki, S., Nakahara, J., Hamanaka, K., Takayama, K., Suzuki, N., & Nishino, I. (2016) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp-2016-313166 · Cited by 326
Metadata
- Authors
- Kassardjian, C. D., Lennon, V. A., Alfugham, N. B., Mahler, M., & Milone, M.
- Venue
- JAMA Neurology
- Publisher
- American Medical Association (AMA)
- Published
- 2015-09-01
- Volume
- 72
- Issue
- 9
- Pages
- 996
- ISSN
- 2168-6149 (ISSN-L)
- OpenAlex
- W1552518697
- Cited by
- 240
- References
- 0
- FWCI
- 12.84
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Clinical Features and Treatment Outcomes of Necrotizing Autoimmune Myopathy. https://app.cochat.ai/papers/10.1001/jamaneurol.2015.1207
- The paper
- Kassardjian, C. D., Lennon, V. A., Alfugham, N. B., Mahler, M., & Milone, M. (2015). Clinical Features and Treatment Outcomes of Necrotizing Autoimmune Myopathy. JAMA Neurology. https://doi.org/10.1001/jamaneurol.2015.1207
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.